These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15357042)

  • 21. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
    Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
    Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal toxicity due to inhaled tobramycin in lung transplant recipients.
    Laporta R; Ussetti P; Carreño MC
    J Heart Lung Transplant; 2006 May; 25(5):608. PubMed ID: 16678043
    [No Abstract]   [Full Text] [Related]  

  • 23. Inhaled tobramycin: not just for cystic fibrosis anymore?
    Lobue PA
    Chest; 2005 Apr; 127(4):1098-101. PubMed ID: 15821180
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland.
    Stelmach I; Korzeniewska A; Stelmach W
    Respiration; 2008; 75(2):178-81. PubMed ID: 17435382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients.
    Stehling F; Büscher R; Grosse-Onnebrink J; Hoyer PF; Mellies U
    Pulm Med; 2017; 2017():2602653. PubMed ID: 28133546
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term effect of chronic intravenous and inhaled nephrotoxic antibiotic treatment on the renal function of patients with cystic fibrosis.
    Florescu MC; Lyden E; Murphy PJ; Florescu DF; Fillaus J
    Hemodial Int; 2012 Jul; 16(3):414-9. PubMed ID: 22469183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of Tobramycin Inhalation Therapy in Patients with Noncystic Fibrosis Bronchiectasis with
    Tanriverdi E; Yildirim BZ; Gul S; Chousein EGU; Turan D; Çınarka H; Özgül MA; Cetinkaya E
    J Aerosol Med Pulm Drug Deliv; 2021 Sep; 34(5):274-279. PubMed ID: 33351705
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
    Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
    J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis.
    Scheinberg P; Shore E
    Chest; 2005 Apr; 127(4):1420-6. PubMed ID: 15821224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
    Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B;
    Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
    Griese M; Müller I; Reinhardt D
    Eur J Med Res; 2002 Feb; 7(2):79-80. PubMed ID: 11891148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis.
    Regnault A; Balp MM; Kulich K; Viala-Danten M
    J Cyst Fibros; 2012 Dec; 11(6):494-501. PubMed ID: 22583743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhaled tobramycin (TOBI).
    Bonsignore CL
    Pediatr Nurs; 1998; 24(3):258-9. PubMed ID: 9987427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
    Ratjen F; Munck A; Kho P; Angyalosi G;
    Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
    Woodward TC; Brown R; Sacco P; Zhang J
    J Med Econ; 2010; 13(3):492-9. PubMed ID: 20670159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ototoxicity of tobramycin in humans - influence of renal impairment.
    Brogard JM; Conraux C; Collard M; Lavillaureix J
    Int J Clin Pharmacol Ther Toxicol; 1982 Sep; 20(9):408-16. PubMed ID: 6982875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Skin contamination leading to falsely elevated fingerprick tobramycin levels in a patient taking dry powder inhaled tobramycin.
    Barry PJ; Jones AM
    J Cyst Fibros; 2014 Dec; 13(6):754. PubMed ID: 24795286
    [No Abstract]   [Full Text] [Related]  

  • 39. [Inhaled antibiotic therapy in cystic fibrosis].
    Girón Moreno RM; Salcedo Posadas A; Mar Gómez-Punter R
    Arch Bronconeumol; 2011 Jun; 47 Suppl 6():14-8. PubMed ID: 21703474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Desensitization to inhaled aztreonam lysine in an allergic patient with cystic fibrosis using a novel approach.
    Guglani L; Abdulhamid I; Ditouras J; Montejo J
    Ann Pharmacother; 2012 Oct; 46(10):e25. PubMed ID: 23012384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.